|
|
Vaccine Detail
|
Melanoma-specific Melan-A/Mart-1 peptide + virus-like nanoparticles |
| Vaccine Information |
- Vaccine Name: Melanoma-specific Melan-A/Mart-1 peptide + virus-like nanoparticles
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007642
- Type: Nanoparticle Vaccine, Peptide
- Status: Research
- Antigen: Melan-A/Mart-1
- Preparation: Linked the melanoma-specific Melan-A/Mart-1 peptide to virus-like nanoparticles loaded with A-type CpG, a ligand for toll-like receptor 9 (Speiser et al., 2010).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: 14/22 patients generated ex vivo detectable T-cell responses, with in part multifunctional T cells capable to degranulate and produce IFN-γ, TNF-α, and IL-2. relatively large fractions of responding specific T cells exhibited a central memory phenotype, more than what is achieved by other nonlive vaccines (Speiser et al., 2010).
|
| References |
Speiser et al., 2010: Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W, Walden P, Zippelius A, Conzett KB, Senti G, Voelter V, Cerottini JP, Guggisberg D, Willers J, Geldhof C, Romero P, Kündig T, Knuth A, Dummer R, Trefzer U, Bachmann MF. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010; 33(8); 848-858. [PubMed: 20842051].
|
|
